DESTINY-Breast03 Phase 3 Study Results
Progression-Free Survival Probability (%)
100
60
80
PFS in HR+ and All Patients
Hormone receptor-positive
Hazard ratio: 0.51
95% CI, 0.40-0.64
P<0.0001
60
A 4.7 mo
T-DXd
mPFS: 10.1 mo
TPC
mPFS: 5.4 mo
Progression-Free Survival Probability (%)
10
Daiichi-Sankyo
DESTINY-Breast04
100
All patients
Hazard ratio: 0.50
95% CI, 0.40-0.63
P < 0.0001
80
60
A 4.8 mo
T-DXd
mPFS: 9.9 mo
40
40
20
TPC
mPFS: 5.1 mo
0
0
T
T
T
T
T
T
T
0
1
2
3
4
5
6 7
8
9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29
Months
0
1 2 3 4 5 6 7
8
9
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29
Months
No. at Risk
No. at Risk
T-DXd (n = 331):
TPC (n = 163):
331 324 290 265 262 248 218 198 182 165 142 128 107 89 78 73 64 48 37 31 28 17 14 12 7 4 4 1 1 0
163 146 105 85 84 69 57 48 43 32 30 27 24 20 14 12 8 4 3 2 1 1 1 1
1 0
1
T-DXD (n = 373):
TPC (n=184):
373 365 325 295 290 272 238 217 201 183 156 142 118 100 88 81 71 53 42 35 32 21 18 15 8 4 4 1 1 0
184 166 119 93 90 73 60 51 45 34 32 29 26 22 15 13 9 5 4 3 1 1 1 1 1 1 0
PFS by blinded independent central review.
HR, hormone receptor; mPFS, median progression-free survival; PFS, progression-free survival; T-DXd, trastuzumab deruxtecan; TPC, treatment of physician's choice.
ASCO 2022 #LBA3 Plenary Session
12View entire presentation